PMID- 30018258 OWN - NLM STAT- MEDLINE DCOM- 20181029 LR - 20230928 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 19 IP - 7 DP - 2018 Jul 17 TI - Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8. LID - 10.3390/ijms19072080 [doi] LID - 2080 AB - High-grade serous ovarian carcinoma (HGSOC) is the most frequent histological type of ovarian cancer and the one with worst prognosis. Unfortunately, the majority of established ovarian cancer cell lines which are used in the research have unclear histological origin and probably do not represent HGSOC. Thus, new and reliable models of HGSOC are needed. Ascitic fluid from a patient with recurrent HGSOC was used to establish a stable cancer cell line. Cells were characterized by cytogenetic karyotyping and short tandem repeat (STR) profiling. New generation sequencing was applied to test for hot-spot mutations in 50 cancer-associated genes and fluorescence in situ hybridization (FISH) analysis was used to check for TP53 status. Cells were analyzed for expression of several marker genes/proteins by reverse-transcription polymerase chain reaction (RT-PCR), fluorescence-activated cell sorting (FACS), and immunocytochemistry (ICC). Functional tests were performed to compare OVPA8 cells with five commercially available and frequently used ovarian cancer cell lines: SKOV3, A2780, OVCAR3, ES2, and OAW42. Our newly-established OVPA8 cell line shows morphologic and genetic features consistent with HGSOC, such as epithelial morphology, multiple chromosomal aberrations, TP53 mutation, BRCA1 mutation, and loss of one copy of BRCA2. The OVPA8 line has a stable STR profile. Cells are positive for EpCAM, CK19, and CD44; they have relatively low plating efficiency/ability to form spheroids, a low migration rate, and intermediate invasiveness in matrigel, as compared to other ovarian cancer lines. OVPA8 is sensitive to paclitaxel and resistant to cisplatin. We also tested two FGFR inhibitors; OVPA8 cells were resistant to AZD4547 (AstraZeneca, London, UK), but sensitive to the new inhibitor CPL304-110-01 (Celon Pharma, Lomianki/Kielpin, Poland). We have established and characterized a novel cell line, OVPA8, which can be a valuable preclinical model for studies on high-grade serous ovarian cancer. FAU - Tudrej, Patrycja AU - Tudrej P AD - Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. patrycja.tudrej@io.gliwice.pl. FAU - Olbryt, Magdalena AU - Olbryt M AD - Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. magdalena.olbryt@io.gliwice.pl. FAU - Zembala-Nozynska, Ewa AU - Zembala-Nozynska E AD - Thumor Pathology Department, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. ewa.zembala-nozynska@io.gliwice.pl. FAU - Kujawa, Katarzyna A AU - Kujawa KA AD - Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. katarzyna.kujawa@io.gliwice.pl. FAU - Cortez, Alexander J AU - Cortez AJ AD - Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. alexander.cortez@io.gliwice.pl. FAU - Fiszer-Kierzkowska, Anna AU - Fiszer-Kierzkowska A AD - Molecular Diagnostics Laboratory, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. anna.fiszer-kierzkowska@io.gliwice.pl. FAU - Piglowski, Wojciech AU - Piglowski W AD - Molecular Diagnostics Laboratory, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. wojciech.piglowski@io.gliwice.pl. FAU - Nikiel, Barbara AU - Nikiel B AD - Thumor Pathology Department, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. barbara.nikiel@io.gliwice.pl. FAU - Glowala-Kosinska, Magdalena AU - Glowala-Kosinska M AD - Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. magdalena.glowala-kosinska@io.gliwice.pl. FAU - Bartkowska-Chrobok, Aleksandra AU - Bartkowska-Chrobok A AD - Department of Hematology and Bone Marrow Transplantation, Andrzej Mielecki Independent Public Hospital, ul. Dabrowskiego 25, 40-032 Katowice, Poland. labhem@spskm.katowice.pl. FAU - Smagur, Andrzej AU - Smagur A AUID- ORCID: 0000-0002-6722-8881 AD - Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. andrzej.smagur@io.gliwice.pl. FAU - Fidyk, Wojciech AU - Fidyk W AUID- ORCID: 0000-0002-5953-7131 AD - Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. wojciech.fidyk@io.gliwice.pl. FAU - Lisowska, Katarzyna M AU - Lisowska KM AUID- ORCID: 0000-0001-9786-3993 AD - Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowskaj-Curie Institute-Oncology Center, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland. katarzyna.lisowska@io.gliwice.pl. LA - eng PT - Journal Article DEP - 20180717 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (BRCA1 Protein) RN - 0 (BRCA1 protein, human) RN - 0 (BRCA2 Protein) RN - 0 (BRCA2 protein, human) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - BRCA1 Protein MH - BRCA2 Protein MH - Cell Line, Tumor MH - Chromosome Aberrations MH - Cystadenocarcinoma, Serous/genetics/metabolism/*pathology MH - Female MH - Genetic Predisposition to Disease/genetics MH - High-Throughput Nucleotide Sequencing/methods MH - Humans MH - Karyotyping MH - Mutation MH - Neoplasm Grading MH - Ovarian Neoplasms/genetics/metabolism/*pathology MH - Tandem Repeat Sequences/genetics MH - Tumor Suppressor Protein p53/genetics/metabolism PMC - PMC6073376 OTO - NOTNLM OT - cell line OT - fibroblast growth factor inhibitor CPL304-110-01 OT - high-grade serous ovarian cancer COIS- The authors declare no conflict of interest. EDAT- 2018/07/19 06:00 MHDA- 2018/10/30 06:00 PMCR- 2018/07/01 CRDT- 2018/07/19 06:00 PHST- 2018/06/06 00:00 [received] PHST- 2018/07/10 00:00 [revised] PHST- 2018/07/13 00:00 [accepted] PHST- 2018/07/19 06:00 [entrez] PHST- 2018/07/19 06:00 [pubmed] PHST- 2018/10/30 06:00 [medline] PHST- 2018/07/01 00:00 [pmc-release] AID - ijms19072080 [pii] AID - ijms-19-02080 [pii] AID - 10.3390/ijms19072080 [doi] PST - epublish SO - Int J Mol Sci. 2018 Jul 17;19(7):2080. doi: 10.3390/ijms19072080.